Rep. Josh Gottheimer Sells Sysmex Corporation ADR (OTCMKTS:SSMXY) Shares

Key Points

• Representative Josh Gottheimer sold shares of Sysmex Corporation ADR for between $1,001 and $15,000 on August 21st, as disclosed in a filing.
• Sysmex reported a loss of earnings per share of $0.05 for its last quarterly earnings, missing analysts' expectations by $0.07.
• The stock has recently been upgraded from a "strong sell" to a "hold" rating by Zacks Research, with analysts generally maintaining a "hold" consensus rating.

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Sysmex Corporation ADR OTCMKTS: SSMXY. In a filing disclosed on September 05th, the Representative disclosed that they had sold between $1,001 and $15,000 in Sysmex stock on August 21st. The trade occurred in the Representative's "MORGAN STANLEY - SELECT UMA ACCOUNT # 1" account.

Representative Josh Gottheimer also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Natera NASDAQ: NTRA on 8/22/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 8/12/2025.
• Sold $1,001 - $15,000 in shares of International Business Machines NYSE: IBM on 8/12/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 8/1/2025.
• Sold $1,001 - $15,000 in shares of Walmart NYSE: WMT on 7/28/2025.
• Sold $1,001 - $15,000 in shares of International Business Machines NYSE: IBM on 7/25/2025.
• Sold $1,001 - $15,000 in shares of Natera NASDAQ: NTRA on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 7/18/2025.
• Sold $1,001 - $15,000 in shares of Independence Realty Trust NYSE: IRT on 7/16/2025.
• Sold $1,001 - $15,000 in shares of Visa NYSE: V on 7/14/2025.

Sysmex Stock Down 1.2%

SSMXY traded down $0.16 during trading on Friday, reaching $12.72. The stock had a trading volume of 87,700 shares, compared to its average volume of 126,519. The company has a current ratio of 3.37, a quick ratio of 2.49 and a debt-to-equity ratio of 0.12. Sysmex Corporation ADR has a one year low of $12.29 and a one year high of $22.00. The company has a market capitalization of $8.01 billion, a price-to-earnings ratio of 25.44 and a beta of 1.10. The stock's 50 day moving average is $14.77 and its two-hundred day moving average is $16.82.

Sysmex (OTCMKTS:SSMXY - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.07). Sysmex had a return on equity of 10.20% and a net margin of 9.35%.The firm had revenue of $717.09 million during the quarter, compared to analysts' expectations of $807.27 million. As a group, analysts expect that Sysmex Corporation ADR will post 0.57 earnings per share for the current year.

Analyst Ratings Changes

Separately, Zacks Research raised Sysmex from a "strong sell" rating to a "hold" rating in a research report on Thursday, August 14th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold".

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey's 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027. Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey's 5th Congressional District. He declared candidacy for the 2026 election. Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025. Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Sysmex Company Profile

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.